ArticleMolecular oncology2020

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.

Thomas Urup et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.